Jonathan Henderson, MD

Beyond radioligands, Henderson points to a number of novel therapeutic categories under investigation.

Henderson emphasized the evolving role of advanced biomarkers in refining prostate cancer risk assessment beyond traditional PSA testing

Jonathan Henderson, MD, recaps his LUGPA 2025 session, “Lessons Learned: Avoiding Pitfalls in Urology Practice Management.”

“We have an incredible opportunity to save countless more lives with better screening practices and renewed recommendations, which accurately reflect the realities we as independent physicians see within our patient populations every day,” Jonathan Henderson, MD, writes in this letter to the editor.